Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising geriatric population
3.2.1.2 Advancements in vaccine development
3.2.1.3 Favourable reimbursement policies
3.2.1.4 Growing awareness about shingles and its complications
3.2.2 Industry pitfalls and challenges
3.2.2.1 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pricing analysis, 2023
3.6 Pipeline analysis
3.7 Technology landscape
3.8 Future market trends
3.9 Gap analysis
3.10 Porter’s analysis
3.11 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)
5.1 Key trends
5.2 Shingrix
5.3 Zostavax
5.4 SKYZoster
Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 – 2034 ($ Mn)
6.1 Key trends
6.2 Recombinant vaccine
6.3 Live attenuated vaccine
Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Netherlands
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.6 Middle East and Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
Chapter 8 Company Profiles
8.1 GSK plc
8.2 Merck & Co.
8.3 SK bioscience
